Correlation of FCGRT genomic structure with serum immunoglobulin, albumin and farletuzumab pharmacokinetics in patients with first relapsed ovarian cancer

Autor: Charles Schweizer, Nicholas C. Nicolaides, Rhonda Meredith, Wenquan Wang, Katie Bendas, Elizabeth B. Somers, Luigi Grasso, Mark Landers, Earl Albone, Jason Wustner, Daniel J. O'Shannessy, Susan C. Weil
Rok vydání: 2017
Předmět:
Zdroj: Genomics. 109:251-257
ISSN: 0888-7543
DOI: 10.1016/j.ygeno.2017.04.006
Popis: Farletuzumab (FAR) is a humanized monoclonal antibody (mAb) that binds to folate receptor alpha. A Ph3 trial in ovarian cancer patients treated with carboplatin/taxane plus FAR or placebo did not meet the primary statistical endpoint. Subgroup analysis demonstrated that subjects with high FAR exposure levels (Cmin>57.6μg/mL) showed statistically significant improvements in PFS and OS. The neonatal Fc receptor (fcgrt) plays a central role in albumin/IgG stasis and mAb pharmacokinetics (PK). Here we evaluated fcgrt sequence and association of its promoter variable number tandem repeats (VNTR) and coding single nucleotide variants (SNV) with albumin/IgG levels and FAR PK in the Ph3 patients. A statistical correlation existed between high FAR Cmin and AUC in patients with the highest quartile of albumin and lowest quartile of IgG1. Analysis of fcgrt identified 5 different VNTRs in the promoter region and 9 SNVs within the coding region, 4 which are novel.
Databáze: OpenAIRE